Lt-02 (modified-release pc pellets)    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
97Ulcerative colitis2

97. Ulcerative colitis    [ 2,269 clinical trials,   1,331 drugs,   (DrugBank: 241 drugs),   114 drug target genes,   181 drug target pathways]
Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 2,269 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-007952-90-LT
(EUCTR)
23/11/200915/09/2009A randomized, multi-center, doubleblind, parallel group, placebocontrolled, phase IIb, dose ranging study to investigate the efficacy and safety of LT-02 in patients with mesalazine-refractory ulcerative colitis.A randomized, multi-center, doubleblind, parallel group, placebocontrolled, phase IIb, dose ranging study to investigate the efficacy and safety of LT-02 in patients with mesalazine-refractory ulcerative colitis. Patients with ulcerative colitis (UC) according to European Crohn's and Colitis Organisation (ECCO) consensus; Simple Clinical Colitis Activity Index (SCCAI) =5 and SCCAI subscore for blood in stool” =2 at Baseline Visit.
MedDRA version: 12.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis
Product Name: LT-02 (modified-release PC pellets)
Product Code: LT-02
INN or Proposed INN: Modified-release phosphatidylcholine
Product Name: LT-02 (modified-release PC pellets)
Product Code: LT-02
INN or Proposed INN: Modified-release phosphatidylcholine
Product Name: LT-02 (modified-release PC pellets)
Product Code: LT-02
INN or Proposed INN: Modified-release phosphatidylcholine
Lipid Therapeutics GmbHNULLNot RecruitingFemale: yes
Male: yes
144Phase 2bGermany;Lithuania
2EUCTR2008-007952-90-DE
(EUCTR)
17/11/200904/08/2009A randomized, multi-center, doubleblind, parallel group, placebocontrolled, phase IIb, dose ranging study to investigate the efficacy and safety of LT-02 in patients with mesalazine-refractory ulcerative colitis. - Amendment No. 3 (Version 1.0), 16-JUL-2010A randomized, multi-center, doubleblind, parallel group, placebocontrolled, phase IIb, dose ranging study to investigate the efficacy and safety of LT-02 in patients with mesalazine-refractory ulcerative colitis. - Amendment No. 3 (Version 1.0), 16-JUL-2010 Patients with ulcerative colitis (UC) according to European Crohn's and Colitis Organisation (ECCO) consensus; Simple Clinical Colitis Activity Index (SCCAI) =5 and SCCAI subscore for blood in stool” =2 at Baseline Visit.
MedDRA version: 12.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis
Product Name: LT-02 (modified-release PC pellets)
Product Code: LT-02
INN or Proposed INN: Modified-release phosphatidylcholine
Product Name: LT-02 (modified-release PC pellets)
Product Code: LT-02
INN or Proposed INN: Modified-release phosphatidylcholine
Product Name: LT-02 (modified-release PC pellets)
Product Code: LT-02
INN or Proposed INN: Modified-release phosphatidylcholine
Lipid Therapeutics GmbHNULLNot RecruitingFemale: yes
Male: yes
240Phase 2bGermany;Lithuania